Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes.
Xu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler NR, Labaki C, Saliby RM, Dinh K, Horst JT, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee GM, Hurwitz M, McGregor BA, Hirsch MS, Shukla SA, McDermott DF, Signoretti S, Romee R, Choueiri TK, Braun DA. Xu W, et al. Among authors: labaki c. ESMO Open. 2025 Jan 14;10(2):104105. doi: 10.1016/j.esmoop.2024.104105. Online ahead of print. ESMO Open. 2025. PMID: 39813824 Free article.
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Jammihal T, Saliby RM, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon YN, Eid M, Sheshdeh AB, Krajewski KM, Büttner FA, Schwab M, Heng D, Casellas RC, Rai K, Zacharias Millward NM, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri TK, Braun DA, Shukla SA. Jammihal T, et al. Among authors: labaki c. Nat Cancer. 2025 Jan 9. doi: 10.1038/s43018-024-00896-w. Online ahead of print. Nat Cancer. 2025. PMID: 39789182
Single-cell epigenetic profiling reveals an interferon response-high program associated with BAP1 deficiency in kidney cancer.
Camp SY, He MX, Cuoco MS, Saad E, Pimenta E, Meli K, Bakouny Z, Labaki C, Titchen BM, Kang YJ, Horst J, Trowbridge R, Shannon E, Helvie K, Thorner AR, Vigneau S, Mayorga A, Kodali J, Lachmayr H, Bemus M, Park J, Choueiri T, Bi K, Van Allen EM. Camp SY, et al. Among authors: labaki c. bioRxiv [Preprint]. 2024 Nov 18:2024.11.15.623837. doi: 10.1101/2024.11.15.623837. bioRxiv. 2024. PMID: 39605676 Free PMC article. Preprint.
Artificial Intelligence in Gastrointestinal Endoscopy.
Labaki C, Uche-Anya EN, Berzin TM. Labaki C, et al. Gastroenterol Clin North Am. 2024 Dec;53(4):773-786. doi: 10.1016/j.gtc.2024.08.005. Epub 2024 Sep 23. Gastroenterol Clin North Am. 2024. PMID: 39489586 Review.
Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma.
El Zarif T, Semaan K, Eid M, Seo JH, Garinet S, Davidsohn MP, Sahgal P, Fortunato B, Canniff J, Nassar AH, Abou Alaiwi S, Bakouny Z, Lakshminarayanan G, Savignano H, Lyons K, Matar S, Ali A, Saad E, Saliby RM, Cordeiro P, Zhang Z, El Ahmar N, Laimon YN, Labaki C, Shah V, Freeman D, O'Toole J, Lee GM, Hwang J, Pomerantz M, Signoretti S, Van Allen EM, Xie W, Berchuck JE, Viswanathan SR, Braun DA, Choueiri TK, Freedman ML, Baca SC. El Zarif T, et al. Among authors: labaki c. Cell Rep. 2024 Jun 25;43(6):114350. doi: 10.1016/j.celrep.2024.114350. Epub 2024 Jun 12. Cell Rep. 2024. PMID: 38870013 Free article.
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
Saad E, Gebrael G, Semaan K, Eid M, Saliby RM, Labaki C, Sayegh N, Wells JC, Takemura K, Ernst MS, Lemelin A, Basappa NS, Wood LA, Powles T, Ernst DS, Lalani AA, Agarwal N, Xie W, Heng DYC, Choueiri TK. Saad E, et al. Among authors: labaki c. Oncologist. 2024 Aug 5;29(8):699-706. doi: 10.1093/oncolo/oyae072. Oncologist. 2024. PMID: 38630540 Free PMC article.
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, Saad E, Kane MH, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer RJ, Powles T, Rini BI, Albiges L, Pal SK, McGregor BA, McKay RR, Signoretti S, Van Allen EM, Shukla SA, Choueiri TK, Braun DA. Saliby RM, et al. Among authors: labaki c. Cancer Cell. 2024 May 13;42(5):732-735. doi: 10.1016/j.ccell.2024.03.002. Epub 2024 Apr 4. Cancer Cell. 2024. PMID: 38579722
Integrative Analysis of Germline Rare Variants in Clear and Non-clear Cell Renal Cell Carcinoma.
Han SH, Camp SY, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker CA, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri TK, AlDubayan SH, Van Allen EM. Han SH, et al. Among authors: labaki c. Eur Urol Open Sci. 2024 Mar 8;62:107-122. doi: 10.1016/j.euros.2024.02.006. eCollection 2024 Apr. Eur Urol Open Sci. 2024. PMID: 38496821 Free PMC article.
69 results